Open Access Peer-Reviewed

Oral L-carnitine and pregnancy: real opportunity for narcoleptic women?

Andrea Romigi1,; Diego Centonze1

DOI: 10.5935/1984-0063.20190060

Citation: Romigi A, Centonze D. Oral L-carnitine and pregnancy: real opportunity for narcoleptic women?. 12(2):124. doi:10.5935/1984-0063.20190060
Received: February 25 2019; Accepted: April 08 2019

We read with great interest the case by Barros et al.1 who described a young female with narcolepsy type 1 who replaced escitalopram (20 mg per day) and modafinil (400 mg per day) with L-carnitine 510 mg/d during pregnancy. The previous treatment induced a quite improvement of somnolence (Epworth Sleepiness Scale score 23/24 to 19/24) and cataplexy (10 episodes/d to 2 episodes per week). During pregnancy, L-carnitine induced a mild improvement of ESS score (20/24) and cataplexy (ten episodes per month). The authors stated that the patient had a good outcome, delivery and breastfeeding were without complications. We previously described a case of narcolepsy type 2, who started oral L-carnitine therapy up to 500 mg b.i.d.2. The patient obtained sustained objective (MSLT) and subjective (ESS) improvement until 6-month follow up after the delivery. Pregnancy is considered a physiological condition of L-carnitine deficiency3 and its use during pregnancy is safe and may ameliorate pregnancy outcome4. In particular L-carnitine deficiency is involved during pregnancy in the state of resistance to the anorectic and thermogenic actions of hypothalamic cellular signals of energy surplus, which, added to refractoriness to leptin effects, likely contributes to gestational hypersomnia, hyperphagia, and obesity3. The same key areas and similar clinical symptoms were also reported in narcolepsy5,6. Low serum level acylcarnitine were described in narcolepsy, and L-carnitine supplementation may reduce sleepiness7,8. The partial improvement of ESS reported by Barros et al.1 may be explained by a low dose of L-carnitine compared to our case (510 mg/d vs. 1000 mg/d)2. Since narcolepsy treatment during pregnancy is challenging9, L-carnitine may represent a safe and effective treatment, although randomized controlled-study should confirm its efficacy on sleepiness and cataplexy and effective and safe dosages in larger sample.



Barros F, Aguilar ACR, Tufik S, Coelho FM. Oral L-Carnitine used to treat narcoleptic type 1 patient during pregnancy - A case report. Sleep Sci. 2018;11(4):215-6. DOI: 10.5935/1984-0063.20180035 Link DOI
Romigi A, Liguori C, Izzi F, Albanese M, Marchi A, Mancini C, et al. Oral L-carnitine as treatment for narcolepsy without cataplexy during pregnancy: a case report. J Neurol Sci. 2015;348(1-2):282-3. DOI: 10.1016/j.jns.2014.11.025 Link DOI
Martínez de Morentin PB, Lage R, González-García I, Ruíz-Pino F, Martins L, Fernández-Mallo D, et al. Pregnancy induces resistance to the anorectic effect of hypothalamic malonyl-CoA and the thermogenic effect of hypothalamic AMPK inhibition in female rats. Endocrinology. 2015;156(3):947-60. DOI: 10.1210/en.2014-1611 Link DOI
Kim MK, Park JK, Paek SK, Kim JW, Kwak IP, Lee HJ, et al. Effects and pregnancy outcomes of L-carnitine supplementation in culture media for human embryo development from in vitro fertilization. J Obstet Gynaecol Res. 2018;44(11):2059-66. DOI: 10.1111/jog.13763 Link DOI
Ganjavi H, Shapiro CM. Hypocretin/Orexin: a molecular link between sleep, energy regulation, and pleasure. J Neuropsychiatry Clin Neurosci. 2007;19(4):413-9. DOI: 10.1176/jnp.2007.19.4.413 Link DOI
Liguori C, Placidi F, Izzi F, Nuccetelli M, Bernardini S, Sarpa MG, et al. Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. Sleep Breath. 2016;20(1):277-83; discussion 283. DOI: 10.1007/s11325-015-1305-9 Link DOI
Miyagawa T, Kawamura H, Obuchi M, Ikesaki A, Ozaki A, Tokunaga K, et al. Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. PLoS One. 2013;8(1):e53707. DOI: 10.1371/journal.pone.0053707 Link DOI
Miyagawa T, Miyadera H, Tanaka S, Kawashima M, Shimada M, Honda Y, et al. Abnormally low serum acylcarnitine levels in narcolepsy patients. Sleep. 2011;34(3):349-53A.
Maurovich-Horvat E, Kemlink D, Högl B, Frauscher B, Ehrmann L, Geisler P, et al.; European Narcolepsy Network. Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies. J Sleep Res. 2013;22(5):496-512. DOI: 10.1111/jsr.12047 Link DOI